Evidence map›Paper›PMID 40558883›Full record

ArticleJournal of functional biomaterials2025

Diagnostic Value of Superparamagnetic Iron Oxide Nanoparticles as a Tracer for Sentinel Lymph Node Mapping in Early-Stage Cervical Cancer: The Preliminary Clinical Experience.

Marcin A Jedryka, Andrzej Czekanski, Marcin Kryszpin, Tymoteusz Poprawski, Krzysztof Grobelak, Piotr Lepka, Rafał Matkowski

Abstract read
In one paragraph

Article in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marcin A JedrykaDepartment of Oncology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.ORCID 0000-0001-8935-0311
Andrzej CzekanskiDepartment of Oncology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Marcin KryszpinDepartment of Oncologic Gynecology, Lower Silesian Oncology, Hematology and Pulmonology Center, 53-413 Wroclaw, Poland.
Tymoteusz PoprawskiDepartment of Oncologic Gynecology, Lower Silesian Oncology, Hematology and Pulmonology Center, 53-413 Wroclaw, Poland.ORCID 0009-0005-6039-8537
Krzysztof GrobelakDepartment of Oncologic Gynecology, Lower Silesian Oncology, Hematology and Pulmonology Center, 53-413 Wroclaw, Poland.
Piotr LepkaDepartment of Oncology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.ORCID 0000-0001-9751-1218
Rafał MatkowskiDepartment of Oncology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.ORCID 0000-0002-1705-5097

Funding

Polish Ministry of Health SUBZ.C280.25.016
6 · The paper itself

Abstract

Sentinel lymph node (SLN) mapping has been investigated as part of surgical staging in women with early-stage cervical cancer (CC); however, pelvic lymphadenectomy (PLND) remains the standard of care. This study aimed to assess feasibility and safety of SLN detection using superparamagnetic iron oxide (SPIO) nanoparticles as a tracer in CC. Thirty CC patients presumed to be stage I were included in this study with SPIO administered intracervically as a tracer for SLN mapping using a magnetometer and followed by PLND. The endpoints of the study included the proportion of successful SLN detection, the average number of SLNs per patient, and the proportion of pathologically positive results per patient and per node. The diagnostic accuracy of SPIO nanoparticles for detection of metastatic SLNs was evaluated by Receiver Operating Characteristic (ROC) curve analysis, with the area under the ROC curve (AUC) used to demonstrate the studied method's sensitivity. Safety endpoints were a summary of all reported adverse events. SLNs were detected in all cases, bilaterally in 27 patients (90%). The median number of SLNs per patient was 3.5. Four cases had metastatic SLNs. The general malignancy rate per patient was 13.3%, and per node, it was 0.8%. The malignancy detection rate of SLNs was 100% per patient and 80% per node. The AUC of 1.0 (

Indexed as

cervical cancerlymphadenectomymappingnanoparticlesentinel lymph nodesuperparamagnetic iron oxidetracer

Identifiers

PMID40558883
PMCPMC12194405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.